-
Mashup Score: 5Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell Disease in the United States | Annals of Internal Medicine - 1 month(s) ago
Background: Gene therapy is a potential cure for sickle cell disease (SCD). Conventional cost-effectiveness analysis (CEA) does not capture the effects of treatments on disparities in SCD, but distributional CEA (DCEA) uses equity weights to incorporate these considerations. Objective: To compare gene therapy versus standard of care (SOC) in patients with SCD by using conventional CEA and DCEA. Design: Markov model. Data Sources: Claims data and other published sources. Target Population: Birth cohort of patients with SCD. Time Horizon: Lifetime. Perspective: U.S. health system. Intervention: Gene therapy at age 12 years versus SOC. Outcome Measures: Incremental cost-effectiveness ratio (ICER) (in dollars per quality-adjusted life-years [QALYs] gained) and threshold inequality aversion parameter (equity weight). Results of Base-Case Analysis: Gene therapy versus SOC for females yielded 25.5 versus 15.7 (males: 24.4 vs. 15.5) discounted lifetime QALYs at costs of $2.8 million and $1.0 m
Source: www.acpjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Inferior vena cava filters: a framework for evidence-based use - 2 month(s) ago
Venous thromboembolism (VTE) is a common cause of morbidity and mortality. Although most patients can be managed safely with anticoagulation, inferior vena cava filters (IVCFs) represent an important alternative to anticoagulation in a small subset of …
Source: www.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4
Don’t miss what’s happeningPeople on X are the first to know.#tandem24 #bmtsm Hamilton: CD19 therapy drives clonal hematopoiesis and cytopenias. Looked at 69 non-relapsed LBCL CART v 69 autoHCT pts finding higher risk of infections with CARTSign up now to get your own personalized timeline!
Source: x.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 9
Program: Oral and Poster Abstracts Type: Oral Session: 904. Outcomes Research – Non-Malignant Conditions: What to Know: Management Costs and Outcomes in Various Non-Malignant Disorders Hematology Disease Topics & Pathways: Sickle Cell Disease, Clinical Practice (Health Services and Quality), Hemoglobinopathies, Diversity, Equity, and Inclusion (DEI) , Diseases George Goshua, MD, MSc 1, Satoko Ito, MD PhD 1, Karthik Chetlapalli, MS, BS 2, Kunal C Potnis, MD 3 *, Cecelia Calhoun, MD, MBA, MPH 1, Lakshmanan
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20% achieve durable remission with salvage chemoimmunotherapy and consolidative autologous stem cell transplantation (ASCT). The ZUMA-7 (axicabtagene ciloleucel [axi-cel]) and TRANSFORM (lisocabtagene maraleucel [liso-cel]) trials demonstrated superior event-free survival (and, in ZUMA-7, overall survival) in primary-refractory or early-relapsed (high-risk) DLBCL with chimeric antigen receptor T-cell therapy (CAR-T) compared with salvage chemoimmunotherapy and consolidative ASCT; however, list prices for CAR-T exceed $400 000 per infusion. Objective: To determine the cost-effectiveness of second-line CAR-T versus salvage chemoimmunotherapy and consolidative ASCT. Design: State-transition microsimulation model. Data Sources: ZUMA-7, TRANSFORM, other trials, and observational data. Target Population: “High-ris
Source: www.acpjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Paper: Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial - 5 month(s) ago
Program: Oral and Poster Abstracts Type: Oral Session: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Innovative Approaches to GVHD Prevention and Treatment Hematology Disease Topics & Pathways: Research, clinical trials, Biological therapies, Antibody Therapy, adult, Clinical Research, Therapies, Study Population, Human Corey Cutler 1, Haesook T. Kim, PhD 2, Hassan El Banna 1 *, Elizabeth Halloran, BSN, RN 1 *, Emily Matozel 1 *, Vincent Ho, MD 1 *, John Koreth, MD, MBBS,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
#ASH23 Oral#649 Tacrolimus/MTX±Obinutuzumab (1000mg IV 3/6/9/12mo post-HCT) 🌟B cell depletion reduces cGVHD 🌟Obin prior to formation of HYAb was more protective against cGVHD 🌟(Manuscript pending) May be practice-changing for me for ablative matched HCT https://t.co/5L5Mz6awX9 https://t.co/LnHqFrDKbY
-
-
Mashup Score: 3Paper: Metabolic Programming of Hematopoietic Stem Cell Function By Prenatal Folate - 5 month(s) ago
Program: General Sessions Session: Plenary Scientific Session Hematology Disease Topics & Pathways: Research, Fundamental Science, hematopoiesis, immunology, metabolism, Biological Processes, molecular biology, Metabolic Disorders, profiling, Animal model, omic s technologies Brian Krum, MSc 1 *, Noah Huerta 2 *, Victoria Chiou 3 *, Robert Welner, PhD 4, Sweta B Patel, PhD 5 *, Travis Nemkov, PhD 6 * and Anna E Beaudin, PhD 7 1 Department of Pathology, University of Utah, Cottonwood Heights, UT 2 Molecular
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
@SBenbarche @ASH_hematology @MaxStahlMD @MSKCancerCenter @DrCCutler @aamdsif @ASCO @ASHClinicalNews @ASTCT @IMFmyeloma @End_myeloma @RahulBanerjeeMD @HadidiSamer @MM_Hub @Eddie_Cliff @MyelomaTeacher @Myeloma_Society @MyelomaUK #ASH23 #ASHPlenary 5⃣ Prenatal folate deficiency can program hematopoietic stem cell function during development, impacting self-renewal & engraftment potential in adulthood. 🩸Altered adult gene expression & metabolic profiles 🩸Mitochondrial dysfunction https://t.co/8iSFPer6ye
-
-
Mashup Score: 23
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20% achieve durable remission with salvage chemoimmunotherapy and consolidative autologous stem cell transplantation (ASCT). The ZUMA-7 (axicabtagene ciloleucel [axi-cel]) and TRANSFORM (lisocabtagene maraleucel [liso-cel]) trials demonstrated superior event-free survival (and, in ZUMA-7, overall survival) in primary-refractory or early-relapsed (high-risk) DLBCL with chimeric antigen receptor T-cell therapy (CAR-T) compared with salvage chemoimmunotherapy and consolidative ASCT; however, list prices for CAR-T exceed $400 000 per infusion. Objective: To determine the cost-effectiveness of second-line CAR-T versus salvage chemoimmunotherapy and consolidative ASCT. Design: State-transition microsimulation model. Data Sources: ZUMA-7, TRANSFORM, other trials, and observational data. Target Population: “High-ris
Source: www.acpjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20% achieve durable remission with salvage chemoimmunotherapy and consolidative autologous stem cell transplantation (ASCT). The ZUMA-7 (axicabtagene ciloleucel [axi-cel]) and TRANSFORM (lisocabtagene maraleucel [liso-cel]) trials demonstrated superior event-free survival (and, in ZUMA-7, overall survival) in primary-refractory or early-relapsed (high-risk) DLBCL with chimeric antigen receptor T-cell therapy (CAR-T) compared with salvage chemoimmunotherapy and consolidative ASCT; however, list prices for CAR-T exceed $400 000 per infusion. Objective: To determine the cost-effectiveness of second-line CAR-T versus salvage chemoimmunotherapy and consolidative ASCT. Design: State-transition microsimulation model. Data Sources: ZUMA-7, TRANSFORM, other trials, and observational data. Target Population: “High-ris
Source: www.acpjournals.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23
Background: First-line treatment of diffuse large B-cell lymphoma (DLBCL) achieves durable remission in approximately 60% of patients. In relapsed or refractory disease, only about 20% achieve durable remission with salvage chemoimmunotherapy and consolidative autologous stem cell transplantation (ASCT). The ZUMA-7 (axicabtagene ciloleucel [axi-cel]) and TRANSFORM (lisocabtagene maraleucel [liso-cel]) trials demonstrated superior event-free survival (and, in ZUMA-7, overall survival) in primary-refractory or early-relapsed (high-risk) DLBCL with chimeric antigen receptor T-cell therapy (CAR-T) compared with salvage chemoimmunotherapy and consolidative ASCT; however, list prices for CAR-T exceed $400 000 per infusion. Objective: To determine the cost-effectiveness of second-line CAR-T versus salvage chemoimmunotherapy and consolidative ASCT. Design: State-transition microsimulation model. Data Sources: ZUMA-7, TRANSFORM, other trials, and observational data. Target Population: “High-ris
Source: www.acpjournals.orgCategories: General Medicine News, Hem/OncsTweet
Draft decision by @NICEComms: "Exa‑cel is not recommended" (@VertexPharma @AricParnes). Per @GeorgeGoshuaMD's excellent *distributional* cost-effectiveness analysis, this determination should consider a society's desire to correct for inequity: https://t.co/O1u3hF8ELH https://t.co/aL443D3zrs